TY - JOUR
T1 - Gynaecomastia in men with chronic myeloid leukaemia after imatinib
AU - Gambacorti-Passerini, Carlo
AU - Tornaghi, Lucia
AU - Cavagnini, Francesco
AU - Rossi, Pellegrino
AU - Pecori-Giraldi, Francesca
AU - Mariani, Luigi
AU - Cambiaghi, Nadia
AU - Pogliani, Enrico
AU - Corneo, Gianmarco
AU - Gnessi, Lucio
PY - 2003/6/7
Y1 - 2003/6/7
N2 - cKit and platelet-derived growth-factor receptor (PDGFR) are receptor tyrosine kinases expressed in the testis, are involved in testosterone production, and are inhibited by imatinib. We measured hormone concentrations in 38 men receiving imatinib for chronic myeloid leukaemia at baseline and during treatment. Mean follow-up was 23.6 months (SD 7.5). We noted seven cases of gynaecomastia (18%, 95% CI 6-30%). A comparison of hormone concentrations in 21 patients before and during treatment showed that patients who developed gynaecomastia had a reduction in free testosterone concentrations of 29.53 pmol/L (95% CI 11.63-47.43), while patients who did not had a decrease of 6.36 pmol/L (-1.02 to 13.74). In most men with chronic myeloid leukaemia studied here, imatinib was associated with a reduction in the production of testicular hormones and in some, with the development of gynaecomastia.
AB - cKit and platelet-derived growth-factor receptor (PDGFR) are receptor tyrosine kinases expressed in the testis, are involved in testosterone production, and are inhibited by imatinib. We measured hormone concentrations in 38 men receiving imatinib for chronic myeloid leukaemia at baseline and during treatment. Mean follow-up was 23.6 months (SD 7.5). We noted seven cases of gynaecomastia (18%, 95% CI 6-30%). A comparison of hormone concentrations in 21 patients before and during treatment showed that patients who developed gynaecomastia had a reduction in free testosterone concentrations of 29.53 pmol/L (95% CI 11.63-47.43), while patients who did not had a decrease of 6.36 pmol/L (-1.02 to 13.74). In most men with chronic myeloid leukaemia studied here, imatinib was associated with a reduction in the production of testicular hormones and in some, with the development of gynaecomastia.
UR - http://www.scopus.com/inward/record.url?scp=10744230733&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10744230733&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(03)13554-4
DO - 10.1016/S0140-6736(03)13554-4
M3 - Article
C2 - 12801741
AN - SCOPUS:10744230733
VL - 361
SP - 1954
EP - 1956
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 9373
ER -